Key Takeaway: Ribociclib plus fulvestrant maintains Health-Related Quality of Life (HRQOL) while improving survival outcomes compared to placebo. Time to definitive deterioration (TTD) was delayed in the treatment arm.
Study Design & Arms
Randomized comparison of Ribociclib vs Placebo (both with Fulvestrant) in HR+/HER2- advanced breast cancer.
Baseline Quality of Life Scores
Comparison of baseline EORTC QLQ-C30 Global Health and Pain scores between groups. Higher Global Health is better; Lower Pain is better.
Hazard Ratios for Deterioration
Hazard Ratios (HR) < 1.0 indicate a lower risk of deterioration with Ribociclib. Error bars represent 95% Confidence Intervals.
Time to Deterioration (Physical Functioning)
Mean time to definitive deterioration (TTD) ≥10% in Physical Functioning score. Longer is better.
Metric Overview
Summary of all extracted quantitative metrics.
Key Positive Outcomes
Metrics identified as positive outcomes for the Ribociclib arm.
Appendix: Raw Data & Provenance
| ID | Metric | Group | Value | Source |
|---|